Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 30, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,000,000 Ordinary shares of 25 pence each.
- Purchase Date: October 27, 2006.
- Purchase Price: 1,411.5 pence per share.
- Treasury Shares Held: 204,591,678 shares (post-transaction).
- Shares in Issue: 5,783,002,353 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase (2,000,000 shares at 1,411.5 pence) against the company's cash position in other filings.
- Confirm the remaining authorization limit for share buybacks following this transaction.
- Review the impact of the increased Treasury share count on earnings per share (EPS) calculations in subsequent reports.